Biomarkers and the Design of Clinical Trials in Cancer

• Kola I , LandisJ: Can the pharmaceutical industry reduce attrition rates?Nat. Rev. Drug Discov.3 , 711–715 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang W , SargentDJ, MandrekarS: An adaptive dose-finding design incorporating both toxicity and efficacy.Statist. Med.25 , 2365–2383 (2006).
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group: Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95(2001).
   PubMed Web of Science ®Google Scholar
• De Gruttola VG , ClaxP, DeMetsDL et al.: Considerations in the Evaluation of Surrogate End Points in Clinical Trials: summary of a National Institutes of Health Workshop. Control Clin. Trials22(5), 485–502 (2001).
   Google Scholar
• Mildvan D , LandayA, DeGruttolaV, MachadoSG, KaganJ: An approach to the validation of markers for use in AIDS clinical trials.Clin. Infect. Dis.24 , 764–774 (1997).
   PubMed Web of Science ®Google Scholar
• D‘Amico AV , ChenMH, RoehlKA, CatalonaWJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.N. Engl. J. Med.351 , 125–135 (2004).
   PubMed Web of Science ®Google Scholar
• Branford S , HughesTP, RudzkiZ: Monitoring chronic myeloid leukemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.Br. J. Haematol.107 , 587–599 (1999).
   PubMed Web of Science ®Google Scholar
• Hughes TP , KaedaJ, BranfordS et al.: Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.349 , 1423–1432 (2003).
   PubMed Web of Science ®Google Scholar
• Lightcap FS , McCormackTA, PienCS, ChauV, AdamsJ, ElliottPJ: Proteasome inhibition measurements: clinical application.Clin. Chem.46 , 673–683 (2000).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ , StinchcombeTE, MitchellBS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol.20 , 4420–4427 (2002).
   PubMed Web of Science ®Google Scholar
• Frank R , HargreavesR: Clinical biomarkers in drug discovery and development.Nat. Rev. Drug Discov.2566–580 (2003).
   Google Scholar
• Prentice RL : Surrogate end points in clinical trials: definition and operational criteria.Stat. Med.8 , 431–40 (1989).
   PubMed Web of Science ®Google Scholar
• Druker BJ , GuilhotF, O‘BrienSG et al.: 5-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355 , 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Temple R : Are surrogate markers adequate to assess cardiovascular disease drugs?JAMA282 , 790–795 (1999).
   PubMed Web of Science ®Google Scholar
• Bucher HC , GuyattGH, CookDJ, HolbrookA, FinlayAM: Users‘ guides to the medical literature XIX: applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points.JAMA282 , 771–778 (1999).
   PubMed Web of Science ®Google Scholar
• Meyer RM , KouroukisCT: Understanding outcome measures.Evidence-based Oncology2 , 172–176 (2001).
   Google Scholar
• Fleming TR , DeMetsDL: Surrogate end points in clinical trials: are we being misled?Ann. Int. Med.125(7), 605–613 (1999).
   Google Scholar
• Pritchard KI , ShepherdLE, O‘MalleyFP et al.: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med.354 , 2103–2111 (2006).
   PubMed Web of Science ®Google Scholar
• McShane LM , AltmanDG, SauerbreiW, TaubeSE, GionM, ClarkGM: Reporting recommendations for tumour marker prognostic studies.J. Clin. Oncol.23(36), 9067–9072 (2005).
   PubMed Web of Science ®Google Scholar
• Sargent DJ , ConleyBA, AllegraC, ColletteL: Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol.23(9), 2020–2027 (2005).
   PubMed Web of Science ®Google Scholar
• Parulekar WR , EisenhauerEA: Phase I trial design for solid tumor studies of targeted, noncytotoxic agents: theory and practice.J. Natl Cancer Inst.96 , 990–997 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , BukowskiRM: Targeted therapy for metastatic renal cell carcinoma.J. Clin. Oncol.24 , 5601–5608 (2004).
   Google Scholar
• Heft PR , DaughertyCK: Are we taking without giving in return? The ethics of research-related biopsies and the benefit of clinical trial participation.J. Clin. Oncol.24 , 4793–4795 (2006).
   PubMed Web of Science ®Google Scholar
• Kummar S , KindersR, RubinsteinLet al.: Compressing drug development timelines in oncology using phase ’0‘ trials. Nat. Rev. Cancer7 , 131–139 (2007).
   Google Scholar
• Schatzkin A , GailM: The promise and peril of surrogate end points in cancer research.Nat. Rev. Cancer2 , 19–27 (2002).
   Google Scholar
• Echt DS , LiebsonPR, MitchellLBet al.: Mortality and morbidity in patients receiving encainide, fledainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med.324(12), 781–788 (1991).
   PubMed Web of Science ®Google Scholar
• Deininger M , BuchdungerE, DrukerBJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia.Blood105 , 2640–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Sackett DL : Rules of evidence and clinical recommendations on the use of antithrombotic agents.Chest95 , 2–4 (1989).
   PubMed Web of Science ®Google Scholar
• Haynes RB : Loose connections between peer-reviewed clinical journal and clinical practice.Ann. Intern. Med.113 , 724–728 (1990).
   Google Scholar
• Cortes J , GilesF, O‘BrienS, ThomasD: Results of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α.Blood102 , 83–86 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM , TalpezM, O‘BrienSet al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood103 , 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz D , LellouchJ: Explanatory and pragmatic attitudes in therapeutic trials.J. Chronic Dis.20 , 637–648 (1967).
   PubMedGoogle Scholar
• Cochrane AL : Effectiveness and efficacy: random reflections on health services. Nuffield Provincial Hospitals Trust. London, UK (1972).
   Google Scholar
• Bergsland EK : When does the presence of the target predict response to the targeted agent?J. Clin. Oncol.24(2), 213–216 (2006).
   PubMed Web of Science ®Google Scholar
• Jubb AM , HurwitzHI, BaiWet al.: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol.24 , 217–227 (2006).
   PubMed Web of Science ®Google Scholar
• Lindmark G , GerdinB, SundbergCet al.: Prognostic significance of the microvessel count in colorectal cancer. J. Clin. Oncol.14 , 461–466 (1996).
   PubMed Web of Science ®Google Scholar
• Lee JC , ChowNH, WangSTet al.: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer36 , 748–753 (2000).
   PubMed Web of Science ®Google Scholar
• Vasan RS : Biomarkers of cardiovascular disease: molecular basis and practical considerations.Circulation113 , 2335–2362 (2006).
   PubMed Web of Science ®Google Scholar
• Laupacis A , WellsG, RichardsonWS, TugwellP: User‘s guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group.JAMA272(3), 234–237 (1994).
   PubMed Web of Science ®Google Scholar
• CLL Trials Collaborative Group: Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst.91(10), 861–868 (1999).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ , DavisZ, GardinerA, OscierDG, StevensonFK: Unmutated IgVHgenes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood94(6), 1848–1854 (1999).
   PubMed Web of Science ®Google Scholar
• Damle RN , WasilT, FaisFet al.:IgVH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood94(6), 1840–1847 (1999).
   PubMed Web of Science ®Google Scholar
• Rassenti LZ , HuynhL, ToyTLet al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med.351(9), 893–901 (2004).
   PubMed Web of Science ®Google Scholar
• Crespo M , BoschF, VilamorNet al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med.348(18), 1764–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Dohner H , StilgenbauerS, BennerAet al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med.343 , 1910–1916 (2000).
   PubMed Web of Science ®Google Scholar
• Flinn IW , NeubergDS, GreverMRet al.: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol.2525 , 793–798 (2007).
   PubMed Web of Science ®Google Scholar
• Grever MR , LucasDM, DewaldGWet al.: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III trial E2997. J. Clin. Oncol.25 , 799–804 (2007).
   PubMed Web of Science ®Google Scholar
• Berger VW : Does the Prentice criterion validate surrogate end points?Statist. Med.23 , 1571–1578 (2004).
   PubMed Web of Science ®Google Scholar
• Paik S , ShakS, TangGet al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351 , 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenwald A , WrightG, ChanWCet al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N. Engl. J. Med.346 , 1937–1947 (2002).
   PubMed Web of Science ®Google Scholar
• Simon R : Roadmap for developing and validating therapeutically relevant genomic classifiers.J. Clin. Oncol.23(29), 7332–7341 (2002).
   Google Scholar
• Pepe MS , EtzioniR, FengZet al.: Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst.93 , 1054–1061 (2001).
   PubMed Web of Science ®Google Scholar

Websites

• Imatinib mesylate or dasatinib in treating patients with chronic phase chronic myelogenous leukemia. http://clinicaltrials.gov/ct/show/NCT00070499?order=1
   Google Scholar
• Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). http://clinicaltrials.gov/ct/show/NCT0031 180?order=1
   Google Scholar